{"success":true,"data":{"_id":462805281,"filings":[{"Organization":{"Hours":[0],"Total Compensation":[0],"Direct compensation":[0],"Other compensation":[0]},"Basic":{"mission":"Transpoc cultivates open collaboration among a wide range of oncology drug discovery organizations, including academic and medical institutions, emerging drug discovery companies, large biopharmaceutical corporations and disease-based foundations.","primary_activities":"Transpoc is a not-for-profit scientific research organization that will provide its sponsors with unprecedented access to data and large-scale technologies to accelerate the discovery of breakthrough cancer medicines. Transpoc cultivates open collaboration among a wide range of oncology drug discovery organizations, including academic and medical institutions, emerging drug discovery companies, large biopharmaceutical corporations and disease-based foundations.transpoc's purpose: perform scientific research that enables the oncology field to develop and deliver more effective personalized therapies to patients. To that end, transpoc is building sharable, large-scale, integrated and capital-efficient translational oncology platforms and bioinformatics capabilities that enable greater clinical proof-of-concept success in the development of new cancer therapies.genetic diversity in human cancers presents a significant challenge for those developing new treatments. Active collaboration provides the best potential to transform this challenge into opportunity.the success of next-generation precision cancer medicine is dependent on appropriately defining patient populations and matching them to the 'right' treatments for their specific cancers. Genetically characterized cancer cell lines and patient-derived xenograft models are emerging as promising platforms to drive the development of the 'right' treatment options. While these technologies already exist, it is beyond the reach of most companies to develop and maintain them in-house at a scale that is cost effective and scientifically relevant.to address these scale and accessibility issues, transpoc's research platforms offer access to shared global technology and translational research resources. This collaborative approach enables all participants, regardless of size, to access technologies critical for successful precision medicine development in a precompetitive space.","year":2014,"name":"TRANSPOC INC","phone":"6175255004","website":"WWW.TRANSPOCBIO.ORG","type":"990","foreign_countries":["Albania","Andorra","Austria","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","Croatia","Cyprus","Czechia","Denmark","Estonia","Faroe Islands","Finland","France","Germany","Gibraltar","Greece","Greenland","Guernsey","Hungary","Iceland","Ireland","Isle of Man","Italy","Jersey","Kosovo","Latvia","Liechtenstein","Lithuania","Luxembourg","Malta","Moldova","Monaco","Montenegro","Netherlands","North Macedonia","Norway","Poland","Portugal","Romania","Russia","San Marino","Serbia","Slovakia","Slovenia","Spain","Svalbard and Jan Mayen","Sweden","Switzerland","Ukraine","United Kingdom","Vatican City","Åland Islands"],"principal_officer":"MARKUS WARMUTH","year_formation":2013,"state_legal_domicile":"MA","total_volunteers":2,"tax_period_begin":"2014-01-01T00:00:00","tax_period_end":"2014-12-31T00:00:00","address":"300 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139, USA","city":"CAMBRIDGE","state":"MA","country":"USA","zip_code":"02139"},"Governance":{"501c3 determination":true,"Number of voting members":3,"Number of independent voting members":2,"Number of employees total":0,"Total Gross UBI":0,"Net unrelated business taxable income":0,"Number of employees":0,"Prohibited tax shelter transactions":false,"Taxable party notification":false,"Funds to pay premiums":false,"Premiums Paid":false,"Family or business relationship":true,"Delegation of management duties":false,"Conflict of interest policy":true,"Whistle blower policy":true,"Compensation process for CEO":false,"Compensation process for other employees":false,"Changes to organizing documents":false,"Material diversion or misuse":false,"Members or stockholders":false,"Election of board members":false,"Decisions subject to approval":false,"Minutes of governing body":true,"Local chapters":false,"Form 990 provided to governing body":true,"Document retention policy":true,"Investment in joint venture":false,"Independent audit financial statements":true,"Consolidated audit financial statements":false,"Accountant compile or review":false,"Financial statements audited by independent accountant":true,"Audit committee":true,"Federal grant audit required":false,"Audited financial statements separate":true,"Political activities":false,"Donor advised funds":false,"Conservation easements":false,"Collections of art":false,"School":false,"Hospital":false,"Foreign activities":true,"Foreign office":false,"Gaming":false,"Fundraising activities":false,"Professional fundraising":true,"Loan to officer or DQP":false,"Grant to related person":false,"Business relationship through family member":false,"Business relationship with organization":false,"Transfers to exempt non-charitable organization":false},"Revenues":{"value":-2207,"Contributions":{"value":0},"Program revenue":{"value":0},"Investment income":{"value":-2207,"Net investment gain":-2207},"Other revenues":{"value":0}},"Expenses":{"value":909810,"Grant expense":{"value":0},"Total professional fundraising expense":{"value":103687,"Fundraising professional":103687},"Benefits paid to members":{"value":0},"Salaries":{"value":0},"Other expenses":{"value":806123,"Legal":84785,"Accounting":70859,"Other services":467117,"Advertising":1655,"Office expenses":348,"Depreciation and depletion":54120,"Itemized Expenses":{"value":127239,"CELL LINES":100522,"LAB SUPPLIES":15800,"REGULATORY & COMPLIANCE":8381,"BANK FEES":2536}},"Functional Expenses":{"Program Service Expenses":617722,"Management And General Expenses":166909,"Fundraising Expenses":125179}},"Assets":{"value":80849,"Non-interest bearing cash":3548,"Land, building, equipment":75301,"Other assets":2000},"Liabilities":{"value":1263175,"Accounts payable, accrued":33175,"Deferred, revenue":1230000},"Fund balance":{"value":-1182326,"Unrestricted net assets":-1182326},"Form990Details":{"program_service_accomplishments":[{"description":"TRANSPOC IS A NOT-FOR-PROFIT SCIENTIFIC RESEARCH ORGANIZATION THAT WILL PROVIDE ITS SPONSORS WITH UNPRECEDENTED ACCESS TO DATA AND LARGE-SCALE TECHNOLOGIES TO ACCELERATE THE DISCOVERY OF BREAKTHROUGH CANCER MEDICINES. TRANSPOC CULTIVATES OPEN COLLABORATION AMONG A WIDE RANGE OF ONCOLOGY DRUG DISCOVERY ORGANIZATIONS, INCLUDING ACADEMIC AND MEDICAL INSTITUTIONS, EMERGING DRUG DISCOVERY COMPANIES, LARGE BIOPHARMACEUTICAL CORPORATIONS AND DISEASE-BASED FOUNDATIONS.TRANSPOC'S PURPOSE: PERFORM SCIENTIFIC RESEARCH THAT ENABLES THE ONCOLOGY FIELD TO DEVELOP AND DELIVER MORE EFFECTIVE PERSONALIZED THERAPIES TO PATIENTS. TO THAT END, TRANSPOC IS BUILDING SHARABLE, LARGE-SCALE, INTEGRATED AND CAPITAL-EFFICIENT TRANSLATIONAL ONCOLOGY PLATFORMS AND BIOINFORMATICS CAPABILITIES THAT ENABLE GREATER CLINICAL PROOF-OF-CONCEPT SUCCESS IN THE DEVELOPMENT OF NEW CANCER THERAPIES.GENETIC DIVERSITY IN HUMAN CANCERS PRESENTS A SIGNIFICANT CHALLENGE FOR THOSE DEVELOPING NEW TREATMENTS. ACTIVE COLLABORATION PROVIDES THE BEST POTENTIAL TO TRANSFORM THIS CHALLENGE INTO OPPORTUNITY.THE SUCCESS OF NEXT-GENERATION PRECISION CANCER MEDICINE IS DEPENDENT ON APPROPRIATELY DEFINING PATIENT POPULATIONS AND MATCHING THEM TO THE 'RIGHT' TREATMENTS FOR THEIR SPECIFIC CANCERS. GENETICALLY CHARACTERIZED CANCER CELL LINES AND PATIENT-DERIVED XENOGRAFT MODELS ARE EMERGING AS PROMISING PLATFORMS TO DRIVE THE DEVELOPMENT OF THE 'RIGHT' TREATMENT OPTIONS. WHILE THESE TECHNOLOGIES ALREADY EXIST, IT IS BEYOND THE REACH OF MOST COMPANIES TO DEVELOP AND MAINTAIN THEM IN-HOUSE AT A SCALE THAT IS COST EFFECTIVE AND SCIENTIFICALLY RELEVANT.TO ADDRESS THESE SCALE AND ACCESSIBILITY ISSUES, TRANSPOC'S RESEARCH PLATFORMS OFFER ACCESS TO SHARED GLOBAL TECHNOLOGY AND TRANSLATIONAL RESEARCH RESOURCES. THIS COLLABORATIVE APPROACH ENABLES ALL PARTICIPANTS, REGARDLESS OF SIZE, TO ACCESS TECHNOLOGIES CRITICAL FOR SUCCESSFUL PRECISION MEDICINE DEVELOPMENT IN A PRECOMPETITIVE SPACE.","expense":617722}],"functional_expense_allocations":{"legal_fees":{"management_and_general":84785,"total":84785},"accounting_fees":{"management_and_general":70859,"total":70859},"professional_fundraising_fees":{"fundraising":103687,"total":103687},"other_service_fees":{"program_services":447280,"fundraising":19837,"total":467117},"advertising":{"fundraising":1655,"total":1655},"office_expenses":{"management_and_general":348,"total":348},"depreciation_depletion":{"program_services":54120,"total":54120}},"tax_and_disclosure_flags":{"activities_conducted_through_partnership":false,"foreign_financial_account":false,"backup_withholding_compliance":true,"lobbying_activities":false,"deductible_non_cash_contributions":false,"deductible_contributions_of_art":false,"method_of_accounting_accrual":true,"schedule_o_part_iii":true,"schedule_o_part_vi":true,"schedule_o_part_ix":true},"principal_officer_detail":{"person_name":"MARKUS WARMUTH"},"audit_financial_statement_detail":{"accountant_compile_or_review":false,"federal_grant_audit_required":false},"related_party_due_diligence":{"officer_entity_with_business_relationship":false,"officer_mailing_address":false,"related_entity":false,"related_org_controlled_entity":false,"compensation_from_other_sources":false,"excess_benefit_transaction":false,"annual_disclosure_covered_persons":true},"grant_due_diligence":{"grants_to_organizations":false,"grants_to_individuals":false,"more_than_5000_to_organizations":false,"more_than_5000_to_individuals":false},"books_in_care_of_detail":{"phone":"7814199200","business_name_line1":"STEPHEN HAIG ACCOUNTING MANAGEMENT SOLUTIONS INC","address_line1":"800 SOUTH STREET SUITE 195","city":"WALTHAM","state":"MA","zip":"02453"},"contractor_compensation_group":[{"business_name_line1":"EVOTEC","compensation":415900,"services_description":"RESEARCH SUPPORT","foreign_address_line1":"ESSENER BOGEN 7","foreign_city":"HAMBURG","foreign_postal_code":"22419","foreign_country":"GM","name":"EVOTEC","foreign_address":"ESSENER BOGEN 7, HAMBURG, 22419, GM"},{"business_name_line1":"ZYDOWSKY CONSULTANTS","compensation":103687,"services_description":"FUNRAISING CONSULTANT","address_line1":"300 BEALE STREET UNIT 301","city":"SAN FRANCISCO","state":"CA","zip":"94105","name":"ZYDOWSKY CONSULTANTS","address":"300 BEALE STREET UNIT 301, SAN FRANCISCO, CA, 94105"}],"officers_directors_key_employees":[{"person_name":"STEPHEN FRIEND","title":"DIRECTOR","average_hours_per_week":0.1,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"individual_trustee_or_director":true,"name":"STEPHEN FRIEND"},{"person_name":"JOSH SOMMER","title":"DIRECTOR","average_hours_per_week":0.1,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"individual_trustee_or_director":true,"name":"JOSH SOMMER"},{"person_name":"MARKUS WARMUTH","title":"DIRECTOR, PRESIDENT","average_hours_per_week":5.0,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"individual_trustee_or_director":true,"officer":true,"name":"MARKUS WARMUTH"},{"person_name":"YUTAKA ISHIZAKA","title":"SECRETARY","average_hours_per_week":6.0,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"officer":true,"name":"YUTAKA ISHIZAKA"},{"person_name":"TAKESHI HAMANO","title":"TREASURER","average_hours_per_week":1.0,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"officer":true,"name":"TAKESHI HAMANO"}]},"ScheduleA":{"public_charity_status":{"publicly_supported_org_170b1_avi":true},"support_170":{"first_five_years":true,"gifts_grants_contributions":{"value":720713,"current_year_minus1":720713},"total_calendar_year_support":{"value":720713,"current_year_minus1":720713},"amounts_from_substantial_contributors":706299,"public_support_total":14414,"total_support":720713}},"ScheduleB":{"attached":false,"required":false},"ScheduleD":{"land_buildings_equipment":{"equipment":{"other_cost_or_other_basis":90361,"book_value":75301,"depreciation":15060},"total_book_value":75301},"other_liabilities":{"footnote_text":true},"revenue_reconciliation":{"total_revenue_audited_financial_statements":151533,"donated_services_and_use_facilities":153740,"revenue_not_reported":153740,"revenue_subtotal":-2207,"revenue_not_reported_financial_statement":0,"total_revenue_per_990":-2207},"expense_reconciliation":{"total_expenses_audited_financial_statements":1063550,"donated_services_use_facilities":153740,"expenses_not_reported":153740,"expenses_subtotal":909810,"expenses_not_reported_financial_statement":0,"total_expenses_per_990":909810},"supplemental_information":[{"form_and_line_reference":"PART X, LINE 2:","explanation":"THE ORGANIZATION ACCOUNTS FOR THE EFFECT OF ANY UNCERTAIN TAX POSITIONS BASED ON A \"MORE LIKELY THAN NOT\" THRESHOLD TO THE RECOGNITION OF THE TAX POSITIONS BEING SUSTAINED BASED ON THE TECHNICAL MERITS OF THE POSITION UNDER SCRUTINY BY THE APPLICABLE TAXING AUTHORITY. IF A TAX POSITION OR POSITIONS ARE DEEMED TO RESULT IN UNCERTAINTIES OF THOSE POSITIONS, THE UNRECOGNIZED TAX BENEFIT IS ESTIMATED BASED ON A \"CUMULATIVE PROBABILITY ASSESSMENT\" THAT AGGREGATES THE ESTIMATED TAX LIABILITY FOR ALL UNCERTAIN TAX POSITIONS. THE ORGANIZATION HAS IDENTIFIED ITS TAX STATUS AS A TAX EXEMPT ENTITY AS ITS ONLY SIGNIFICANT TAX POSITION; HOWEVER, THE ORGANIZATION HAS DETERMINED THAT SUCH TAX POSITION DOES NOT RESULT IN AN UNCERTAINTY REQUIRING RECOGNITION. THE ORGANIZATION IS NOT CURRENTLY UNDER EXAMINATION BY ANY TAXING JURISDICTION. ITS FEDERAL INCOME TAX RETURNS ARE GENERALLY OPEN FOR EXAMINATION FOR THREE YEARS FOLLOWING THE DATE OF THE FILING OF THE RELATED RETURN."}]},"ScheduleG":{"professional_fundraising":{"agreement_professional_fundraising":true,"total_retained_by_contractors":103687,"licensed_states":["MA"],"fundraisers":[{"business_name_line1":"ZYDOWSKI CONSULTANTS","address_line1":"300 BEALE STREET UNIT 301","city":"SAN FRANCISCO","state":"CA","zip":"94105","activity":"BUSINESS AND FUNDRAISING SERVICES","control_of_funds":false,"gross_receipts":0,"retained_by_contractor":103687,"net_to_organization":0,"name":"ZYDOWSKI CONSULTANTS","address":"300 BEALE STREET UNIT 301, SAN FRANCISCO, CA, 94105"}]}},"ScheduleF":{"regions":[{"region":"EUROPE (INCLUDING ICELAND & GREENLAND)","activity_type":"PROGRAM SERVICE","services":"CELL LINE BANKING AND MAINTENANCE","total_expenditures":415900,"employees":0,"offices":0}],"part_i_totals":{"total_offices":0,"total_employees":0,"total_spent":415900,"subtotal_offices":0,"subtotal_employees":0,"subtotal_spent":415900,"continuation_total_offices":0,"continuation_total_employees":0,"continuation_spent":0},"foreign_forms":{"transfer_to_foreign_corporation":false,"interest_in_foreign_trust":false,"foreign_corporation_ownership":false,"passive_foreign_investment_company":false,"foreign_partnership":false,"boycott_countries":false}},"ScheduleN":{"successor_relationships":{"director_of_successor":false,"employee_of_successor":false,"owner_of_successor":false,"received_compensation":false},"dispositions":[{"business_name_line1":"EVOTEC","irc_section":"CORPORATION","distribution_date":"2014-12-31T00:00:00","description":"SCIENTIFIC EQUIPMENT","fair_market_value":227207,"method_of_fmv_determination":"BOOK VALUE","foreign_address_line1":"ESSENER BOGEN 7","foreign_city":"HAMBURG","foreign_postal_code":"22419","foreign_country":"GM","name":"EVOTEC","foreign_address":"ESSENER BOGEN 7, HAMBURG, 22419, GM"}]},"source_xml":"201543209349302159_public.xml"}],"Latest":{"Organization":{"Hours":[0],"Total Compensation":[0],"Direct compensation":[0],"Other compensation":[0]},"Basic":{"mission":"Transpoc cultivates open collaboration among a wide range of oncology drug discovery organizations, including academic and medical institutions, emerging drug discovery companies, large biopharmaceutical corporations and disease-based foundations.","primary_activities":"Transpoc is a not-for-profit scientific research organization that will provide its sponsors with unprecedented access to data and large-scale technologies to accelerate the discovery of breakthrough cancer medicines. Transpoc cultivates open collaboration among a wide range of oncology drug discovery organizations, including academic and medical institutions, emerging drug discovery companies, large biopharmaceutical corporations and disease-based foundations.transpoc's purpose: perform scientific research that enables the oncology field to develop and deliver more effective personalized therapies to patients. To that end, transpoc is building sharable, large-scale, integrated and capital-efficient translational oncology platforms and bioinformatics capabilities that enable greater clinical proof-of-concept success in the development of new cancer therapies.genetic diversity in human cancers presents a significant challenge for those developing new treatments. Active collaboration provides the best potential to transform this challenge into opportunity.the success of next-generation precision cancer medicine is dependent on appropriately defining patient populations and matching them to the 'right' treatments for their specific cancers. Genetically characterized cancer cell lines and patient-derived xenograft models are emerging as promising platforms to drive the development of the 'right' treatment options. While these technologies already exist, it is beyond the reach of most companies to develop and maintain them in-house at a scale that is cost effective and scientifically relevant.to address these scale and accessibility issues, transpoc's research platforms offer access to shared global technology and translational research resources. This collaborative approach enables all participants, regardless of size, to access technologies critical for successful precision medicine development in a precompetitive space.","year":2014,"name":"TRANSPOC INC","phone":"6175255004","website":"WWW.TRANSPOCBIO.ORG","type":"990","foreign_countries":["Albania","Andorra","Austria","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","Croatia","Cyprus","Czechia","Denmark","Estonia","Faroe Islands","Finland","France","Germany","Gibraltar","Greece","Greenland","Guernsey","Hungary","Iceland","Ireland","Isle of Man","Italy","Jersey","Kosovo","Latvia","Liechtenstein","Lithuania","Luxembourg","Malta","Moldova","Monaco","Montenegro","Netherlands","North Macedonia","Norway","Poland","Portugal","Romania","Russia","San Marino","Serbia","Slovakia","Slovenia","Spain","Svalbard and Jan Mayen","Sweden","Switzerland","Ukraine","United Kingdom","Vatican City","Åland Islands"],"principal_officer":"MARKUS WARMUTH","year_formation":2013,"state_legal_domicile":"MA","total_volunteers":2,"tax_period_begin":"2014-01-01T00:00:00","tax_period_end":"2014-12-31T00:00:00","address":"300 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139, USA","city":"CAMBRIDGE","state":"MA","country":"USA","zip_code":"02139"},"Governance":{"501c3 determination":true,"Number of voting members":3,"Number of independent voting members":2,"Number of employees total":0,"Total Gross UBI":0,"Net unrelated business taxable income":0,"Number of employees":0,"Prohibited tax shelter transactions":false,"Taxable party notification":false,"Funds to pay premiums":false,"Premiums Paid":false,"Family or business relationship":true,"Delegation of management duties":false,"Conflict of interest policy":true,"Whistle blower policy":true,"Compensation process for CEO":false,"Compensation process for other employees":false,"Changes to organizing documents":false,"Material diversion or misuse":false,"Members or stockholders":false,"Election of board members":false,"Decisions subject to approval":false,"Minutes of governing body":true,"Local chapters":false,"Form 990 provided to governing body":true,"Document retention policy":true,"Investment in joint venture":false,"Independent audit financial statements":true,"Consolidated audit financial statements":false,"Accountant compile or review":false,"Financial statements audited by independent accountant":true,"Audit committee":true,"Federal grant audit required":false,"Audited financial statements separate":true,"Political activities":false,"Donor advised funds":false,"Conservation easements":false,"Collections of art":false,"School":false,"Hospital":false,"Foreign activities":true,"Foreign office":false,"Gaming":false,"Fundraising activities":false,"Professional fundraising":true,"Loan to officer or DQP":false,"Grant to related person":false,"Business relationship through family member":false,"Business relationship with organization":false,"Transfers to exempt non-charitable organization":false},"Revenues":{"value":-2207,"Contributions":{"value":0},"Program revenue":{"value":0},"Investment income":{"value":-2207,"Net investment gain":-2207},"Other revenues":{"value":0}},"Expenses":{"value":909810,"Grant expense":{"value":0},"Total professional fundraising expense":{"value":103687,"Fundraising professional":103687},"Benefits paid to members":{"value":0},"Salaries":{"value":0},"Other expenses":{"value":806123,"Legal":84785,"Accounting":70859,"Other services":467117,"Advertising":1655,"Office expenses":348,"Depreciation and depletion":54120,"Itemized Expenses":{"value":127239,"CELL LINES":100522,"LAB SUPPLIES":15800,"REGULATORY & COMPLIANCE":8381,"BANK FEES":2536}},"Functional Expenses":{"Program Service Expenses":617722,"Management And General Expenses":166909,"Fundraising Expenses":125179}},"Assets":{"value":80849,"Non-interest bearing cash":3548,"Land, building, equipment":75301,"Other assets":2000},"Liabilities":{"value":1263175,"Accounts payable, accrued":33175,"Deferred, revenue":1230000},"Fund balance":{"value":-1182326,"Unrestricted net assets":-1182326},"Form990Details":{"program_service_accomplishments":[{"description":"TRANSPOC IS A NOT-FOR-PROFIT SCIENTIFIC RESEARCH ORGANIZATION THAT WILL PROVIDE ITS SPONSORS WITH UNPRECEDENTED ACCESS TO DATA AND LARGE-SCALE TECHNOLOGIES TO ACCELERATE THE DISCOVERY OF BREAKTHROUGH CANCER MEDICINES. TRANSPOC CULTIVATES OPEN COLLABORATION AMONG A WIDE RANGE OF ONCOLOGY DRUG DISCOVERY ORGANIZATIONS, INCLUDING ACADEMIC AND MEDICAL INSTITUTIONS, EMERGING DRUG DISCOVERY COMPANIES, LARGE BIOPHARMACEUTICAL CORPORATIONS AND DISEASE-BASED FOUNDATIONS.TRANSPOC'S PURPOSE: PERFORM SCIENTIFIC RESEARCH THAT ENABLES THE ONCOLOGY FIELD TO DEVELOP AND DELIVER MORE EFFECTIVE PERSONALIZED THERAPIES TO PATIENTS. TO THAT END, TRANSPOC IS BUILDING SHARABLE, LARGE-SCALE, INTEGRATED AND CAPITAL-EFFICIENT TRANSLATIONAL ONCOLOGY PLATFORMS AND BIOINFORMATICS CAPABILITIES THAT ENABLE GREATER CLINICAL PROOF-OF-CONCEPT SUCCESS IN THE DEVELOPMENT OF NEW CANCER THERAPIES.GENETIC DIVERSITY IN HUMAN CANCERS PRESENTS A SIGNIFICANT CHALLENGE FOR THOSE DEVELOPING NEW TREATMENTS. ACTIVE COLLABORATION PROVIDES THE BEST POTENTIAL TO TRANSFORM THIS CHALLENGE INTO OPPORTUNITY.THE SUCCESS OF NEXT-GENERATION PRECISION CANCER MEDICINE IS DEPENDENT ON APPROPRIATELY DEFINING PATIENT POPULATIONS AND MATCHING THEM TO THE 'RIGHT' TREATMENTS FOR THEIR SPECIFIC CANCERS. GENETICALLY CHARACTERIZED CANCER CELL LINES AND PATIENT-DERIVED XENOGRAFT MODELS ARE EMERGING AS PROMISING PLATFORMS TO DRIVE THE DEVELOPMENT OF THE 'RIGHT' TREATMENT OPTIONS. WHILE THESE TECHNOLOGIES ALREADY EXIST, IT IS BEYOND THE REACH OF MOST COMPANIES TO DEVELOP AND MAINTAIN THEM IN-HOUSE AT A SCALE THAT IS COST EFFECTIVE AND SCIENTIFICALLY RELEVANT.TO ADDRESS THESE SCALE AND ACCESSIBILITY ISSUES, TRANSPOC'S RESEARCH PLATFORMS OFFER ACCESS TO SHARED GLOBAL TECHNOLOGY AND TRANSLATIONAL RESEARCH RESOURCES. THIS COLLABORATIVE APPROACH ENABLES ALL PARTICIPANTS, REGARDLESS OF SIZE, TO ACCESS TECHNOLOGIES CRITICAL FOR SUCCESSFUL PRECISION MEDICINE DEVELOPMENT IN A PRECOMPETITIVE SPACE.","expense":617722}],"functional_expense_allocations":{"legal_fees":{"management_and_general":84785,"total":84785},"accounting_fees":{"management_and_general":70859,"total":70859},"professional_fundraising_fees":{"fundraising":103687,"total":103687},"other_service_fees":{"program_services":447280,"fundraising":19837,"total":467117},"advertising":{"fundraising":1655,"total":1655},"office_expenses":{"management_and_general":348,"total":348},"depreciation_depletion":{"program_services":54120,"total":54120}},"tax_and_disclosure_flags":{"activities_conducted_through_partnership":false,"foreign_financial_account":false,"backup_withholding_compliance":true,"lobbying_activities":false,"deductible_non_cash_contributions":false,"deductible_contributions_of_art":false,"method_of_accounting_accrual":true,"schedule_o_part_iii":true,"schedule_o_part_vi":true,"schedule_o_part_ix":true},"principal_officer_detail":{"person_name":"MARKUS WARMUTH"},"audit_financial_statement_detail":{"accountant_compile_or_review":false,"federal_grant_audit_required":false},"related_party_due_diligence":{"officer_entity_with_business_relationship":false,"officer_mailing_address":false,"related_entity":false,"related_org_controlled_entity":false,"compensation_from_other_sources":false,"excess_benefit_transaction":false,"annual_disclosure_covered_persons":true},"grant_due_diligence":{"grants_to_organizations":false,"grants_to_individuals":false,"more_than_5000_to_organizations":false,"more_than_5000_to_individuals":false},"books_in_care_of_detail":{"phone":"7814199200","business_name_line1":"STEPHEN HAIG ACCOUNTING MANAGEMENT SOLUTIONS INC","address_line1":"800 SOUTH STREET SUITE 195","city":"WALTHAM","state":"MA","zip":"02453"},"contractor_compensation_group":[{"business_name_line1":"EVOTEC","compensation":415900,"services_description":"RESEARCH SUPPORT","foreign_address_line1":"ESSENER BOGEN 7","foreign_city":"HAMBURG","foreign_postal_code":"22419","foreign_country":"GM","name":"EVOTEC","foreign_address":"ESSENER BOGEN 7, HAMBURG, 22419, GM"},{"business_name_line1":"ZYDOWSKY CONSULTANTS","compensation":103687,"services_description":"FUNRAISING CONSULTANT","address_line1":"300 BEALE STREET UNIT 301","city":"SAN FRANCISCO","state":"CA","zip":"94105","name":"ZYDOWSKY CONSULTANTS","address":"300 BEALE STREET UNIT 301, SAN FRANCISCO, CA, 94105"}],"officers_directors_key_employees":[{"person_name":"STEPHEN FRIEND","title":"DIRECTOR","average_hours_per_week":0.1,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"individual_trustee_or_director":true,"name":"STEPHEN FRIEND"},{"person_name":"JOSH SOMMER","title":"DIRECTOR","average_hours_per_week":0.1,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"individual_trustee_or_director":true,"name":"JOSH SOMMER"},{"person_name":"MARKUS WARMUTH","title":"DIRECTOR, PRESIDENT","average_hours_per_week":5.0,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"individual_trustee_or_director":true,"officer":true,"name":"MARKUS WARMUTH"},{"person_name":"YUTAKA ISHIZAKA","title":"SECRETARY","average_hours_per_week":6.0,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"officer":true,"name":"YUTAKA ISHIZAKA"},{"person_name":"TAKESHI HAMANO","title":"TREASURER","average_hours_per_week":1.0,"reportable_comp_from_org":0,"reportable_comp_from_related_orgs":0,"other_compensation":0,"officer":true,"name":"TAKESHI HAMANO"}]},"ScheduleA":{"public_charity_status":{"publicly_supported_org_170b1_avi":true},"support_170":{"first_five_years":true,"gifts_grants_contributions":{"value":720713,"current_year_minus1":720713},"total_calendar_year_support":{"value":720713,"current_year_minus1":720713},"amounts_from_substantial_contributors":706299,"public_support_total":14414,"total_support":720713}},"ScheduleB":{"attached":false,"required":false},"ScheduleD":{"land_buildings_equipment":{"equipment":{"other_cost_or_other_basis":90361,"book_value":75301,"depreciation":15060},"total_book_value":75301},"other_liabilities":{"footnote_text":true},"revenue_reconciliation":{"total_revenue_audited_financial_statements":151533,"donated_services_and_use_facilities":153740,"revenue_not_reported":153740,"revenue_subtotal":-2207,"revenue_not_reported_financial_statement":0,"total_revenue_per_990":-2207},"expense_reconciliation":{"total_expenses_audited_financial_statements":1063550,"donated_services_use_facilities":153740,"expenses_not_reported":153740,"expenses_subtotal":909810,"expenses_not_reported_financial_statement":0,"total_expenses_per_990":909810},"supplemental_information":[{"form_and_line_reference":"PART X, LINE 2:","explanation":"THE ORGANIZATION ACCOUNTS FOR THE EFFECT OF ANY UNCERTAIN TAX POSITIONS BASED ON A \"MORE LIKELY THAN NOT\" THRESHOLD TO THE RECOGNITION OF THE TAX POSITIONS BEING SUSTAINED BASED ON THE TECHNICAL MERITS OF THE POSITION UNDER SCRUTINY BY THE APPLICABLE TAXING AUTHORITY. IF A TAX POSITION OR POSITIONS ARE DEEMED TO RESULT IN UNCERTAINTIES OF THOSE POSITIONS, THE UNRECOGNIZED TAX BENEFIT IS ESTIMATED BASED ON A \"CUMULATIVE PROBABILITY ASSESSMENT\" THAT AGGREGATES THE ESTIMATED TAX LIABILITY FOR ALL UNCERTAIN TAX POSITIONS. THE ORGANIZATION HAS IDENTIFIED ITS TAX STATUS AS A TAX EXEMPT ENTITY AS ITS ONLY SIGNIFICANT TAX POSITION; HOWEVER, THE ORGANIZATION HAS DETERMINED THAT SUCH TAX POSITION DOES NOT RESULT IN AN UNCERTAINTY REQUIRING RECOGNITION. THE ORGANIZATION IS NOT CURRENTLY UNDER EXAMINATION BY ANY TAXING JURISDICTION. ITS FEDERAL INCOME TAX RETURNS ARE GENERALLY OPEN FOR EXAMINATION FOR THREE YEARS FOLLOWING THE DATE OF THE FILING OF THE RELATED RETURN."}]},"ScheduleG":{"professional_fundraising":{"agreement_professional_fundraising":true,"total_retained_by_contractors":103687,"licensed_states":["MA"],"fundraisers":[{"business_name_line1":"ZYDOWSKI CONSULTANTS","address_line1":"300 BEALE STREET UNIT 301","city":"SAN FRANCISCO","state":"CA","zip":"94105","activity":"BUSINESS AND FUNDRAISING SERVICES","control_of_funds":false,"gross_receipts":0,"retained_by_contractor":103687,"net_to_organization":0,"name":"ZYDOWSKI CONSULTANTS","address":"300 BEALE STREET UNIT 301, SAN FRANCISCO, CA, 94105"}]}},"ScheduleF":{"regions":[{"region":"EUROPE (INCLUDING ICELAND & GREENLAND)","activity_type":"PROGRAM SERVICE","services":"CELL LINE BANKING AND MAINTENANCE","total_expenditures":415900,"employees":0,"offices":0}],"part_i_totals":{"total_offices":0,"total_employees":0,"total_spent":415900,"subtotal_offices":0,"subtotal_employees":0,"subtotal_spent":415900,"continuation_total_offices":0,"continuation_total_employees":0,"continuation_spent":0},"foreign_forms":{"transfer_to_foreign_corporation":false,"interest_in_foreign_trust":false,"foreign_corporation_ownership":false,"passive_foreign_investment_company":false,"foreign_partnership":false,"boycott_countries":false}},"ScheduleN":{"successor_relationships":{"director_of_successor":false,"employee_of_successor":false,"owner_of_successor":false,"received_compensation":false},"dispositions":[{"business_name_line1":"EVOTEC","irc_section":"CORPORATION","distribution_date":"2014-12-31T00:00:00","description":"SCIENTIFIC EQUIPMENT","fair_market_value":227207,"method_of_fmv_determination":"BOOK VALUE","foreign_address_line1":"ESSENER BOGEN 7","foreign_city":"HAMBURG","foreign_postal_code":"22419","foreign_country":"GM","name":"EVOTEC","foreign_address":"ESSENER BOGEN 7, HAMBURG, 22419, GM"}]},"Ratings":{"Mission Deployment Rate":{"score":null},"Program Expense Ratio":{"score":0.6789571448983853},"Fundraising Efficiency":{"score":0.0,"percentile":0.009927101538267756},"Filing Consistency Score":{"score":1.0},"Grant Itemization Coverage":{"score":null},"Independent Voting Board Pct":{"score":0.6666666666666666},"Operating Margin":{"score":-413.2383325781604,"percentile":0.004267312092561412},"Operating Reserve Ratio":{"score":0.08886360888537168,"percentile":0.11024998615802005},"Liabilities to Assets Ratio":{"score":15.62387908322923,"percentile":0.005977047579182364},"Officer Compensation Ratio":{"score":null,"percentile":null},"Program Expense Growth":{"score":null,"percentile":null},"Revenue Growth":{"score":null,"percentile":null},"Asset Growth":{"score":null,"percentile":null},"Foreign Oversight Score":{"score":null},"Major-Donor Itemization":{"score":null},"Related-Party Transparency":{"score":null},"Pay-Setting Controls":{"score":1.0,"weight":5,"atoms":{"Compensation committee":{"value":true},"Independent compensation consultant":{"value":true},"Form 990 of other organizations reviewed":{"value":true},"Written employment contract":{"value":true},"Compensation survey or study":{"value":true},"Board or committee approval":{"value":true}}},"Governance Policy Score":{"score":0.7777777777777778,"weight":5,"atoms":{"Conflict of interest policy":{"value":true},"Whistle blower policy":{"value":true},"Document retention policy":{"value":true},"Compensation process for CEO":{"value":false},"Compensation process for other employees":{"value":false},"Form 990 provided to governing body":{"value":true},"Minutes of governing body":{"value":true},"Audit committee":{"value":true},"Independent audit financial statements":{"value":true}}},"Categories":{"Financial Efficiency":{"score":0.41134512755433833,"weight":45},"Transparency & Controls":{"score":1.0,"weight":20},"Accountability":{"score":0.7129629629629629,"weight":14},"Sustainability":{"score":0.03982283484593042,"weight":13},"Growth":{"score":null,"weight":8}},"Overall Score":{"score":0.5327142290698239,"percentile":0.09167224160629081}},"source_xml":"201543209349302159_public.xml"},"sector":"Health","donation_categories":[],"zakat_policy":null},"error":null}